Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We will discuss the industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects. This report will focus on research and development as it is now, how it is changing and mutating, and where it has been headed during 2016 and will be in 2017.
Join Alex Shimmings, Executive Editor, Europe, Commercial, Scrip, Pink Sheet, In Vivo and Ian Lloyd, Senior Director, Pharmaprojects and Data Integration - Citeline
as they will share insight on the following key areas:
Total pipeline size – the pharma forest is teeming with life
The 2017 pipeline by phase – Baby boom leads the way, but growth throughout the family
Top companies – Big beasts still dominate, but Novartis is the new king of the jungleTop therapies – Cancer’s herds spread further into the pharma habitat
Types of pipeline drugs – As biologicals proliferate, is the small molecule becoming a dinosaur?
Mechanisms and Targets – how to stay alive in a crowded ecosystem
Survival of the fittest – Darwinian forces mean pharma’s creatures must find their niches
Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year and what they may mean for the pipeline during the year to come. The 27th instalment of the Annual Review, this version takes advantage of improvements to Pharmaprojects’ data granularity to bring you details on pharma R&D trends
Recently, Pharma Intelligence brought you the Pharma R&D Annual Review 2020 Webinar, followed up with the NAS (New Active Substances) Infographic. We now invite you to go even deeper into pharma R&D successes for 2019 with your free copy of the NAS Supplement.
To build and maintain gold-standard, next generation R&D intelligence tools, Sitetrove, Trialtrove, Pharmaprojects, and Trialpredict have been undergoing a major program of investment. In addition to the many new and exciting changes on the horizon, the robust and reliable Citeline tools that you use to inform your business decisions will formally join Informa’s Pharma Intelligence family of brands.
Citeline Engage: Supporting clinical trial planning and execution right from the start
Citeline Engage is our powerful new solution that combines our leading investigator engagement capability with real-world data to help you gather expert feedback on critical business topics, ignite awareness of your upcoming or ongoing trials, and recruit the right investigators for your clinical trials.